Kalaris Posts Positive Results from Macular Degeneration Drug Trial
MT Newswires Live
Dec 18, 2025
Kalaris Therapeutics (KLRS) reported late Wednesday positive initial data from its Phase 1a trial of its investigational drug for treating naive neovascular AMD patients.
The single ascending dose (SAD) trial showed the drug candidate, TH103, had clinically meaningful improvements in vision and retinal anatomy.
The trial also indicated early signs of potential for extended treatment durability.
The company expects to share preliminary data from the ongoing Phase 1b/2 study in the second half of 2026
Shares were down nearly 15% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.